{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:29:49Z","timestamp":1782732589365,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40487-025-00354-2","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:04:39Z","timestamp":1751594679000},"page":"797-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Practical Guidance on the Clinical Management of Ocular Adverse Events Associated with Belantamab Mafodotin for Patients with Relapsed\/Refractory Multiple Myeloma: Latin American Expert Panel Recommendations"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"V\u00e2nia","family":"Hungria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Abello Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Corzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvan Q.","family":"Crusoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel E.","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia A.","family":"Iutaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracia A.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline G.","family":"Ram\u00edrez Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim\u00f3n","family":"Romano-Bucay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio G.","family":"Schlottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian M.","family":"Seehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge C.","family":"Torres Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"354_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"354_CR2","doi-asserted-by":"crossref","unstructured":"Hungria VTdM, Pe\u00f1a C, G\u00f3mez-Almaguer D, Mart\u00ednez-Cordero H, Sch\u00fctz NP, Blunk V. Multiple myeloma in Latin America: a systematic review. eJHaem. 2024;5:867\u201378.","DOI":"10.1002\/jha2.905"},{"key":"354_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"354_CR4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.5004","volume":"22","author":"NS Callander","year":"2024","unstructured":"Callander NS, Kumar SK. Updates to the management of multiple myeloma. J Natl Compr Canc Netw. 2024;22:e245004.","journal-title":"J Natl Compr Canc Netw"},{"key":"354_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","volume":"9","author":"P Moreau","year":"2019","unstructured":"Moreau P, Zamagni E, Mateos MV. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J. 2019;9:38.","journal-title":"Blood Cancer J"},{"key":"354_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/JOP.19.00244","volume":"16","author":"A Branagan","year":"2020","unstructured":"Branagan A, Lei M, Lou U, Raje N. Current treatment strategies for multiple myeloma. JCO Oncol Pract. 2020;16:5\u201314.","journal-title":"JCO Oncol Pract"},{"key":"354_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-023-00804-y","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Mateos MV, Iida S, Reece D. Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. Blood Cancer J. 2023;13:41.","journal-title":"Blood Cancer J"},{"key":"354_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970720.67003.75","volume":"7","author":"V Hungria","year":"2023","unstructured":"Hungria V, Gaiolla R, Galvez K, et al. P954: multiple myeloma in Latin America cancer registry: the MYLACRE study. Hemasphere. 2023;7:e6700375.","journal-title":"Hemasphere"},{"key":"354_CR9","doi-asserted-by":"crossref","unstructured":"Abreu G, Queiroz J, Nogueira da Silva TL, et al. P-320: Real-world evidence of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 in patients with multiple myeloma treated in Brazil: TOTEMM-B study insights. International Myeloma Society (IMS) Annual Meeting; 25\u201328 September 2024; Rio de Janeiro, Brazil.","DOI":"10.1016\/S2152-2650(24)02222-5"},{"key":"354_CR10","doi-asserted-by":"crossref","unstructured":"Abreu G, Queiroz J, Nogueira da Silva TL, et al. P-319: First-line treatment landscape in multiple myeloma: analysis of stem cell transplantation and drug utilization in Argentina and Brazil from the TOTEMM-A and TOTEMM-B real-world studies. International Myeloma Society (IMS) Annual Meeting; 25\u201328 September 2024; Rio de Janeiro, Brazil.","DOI":"10.1016\/S2152-2650(24)02221-3"},{"key":"354_CR11","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/j.clml.2021.12.009","volume":"22","author":"V Abello","year":"2022","unstructured":"Abello V, Mantilla WA, Idrobo H, et al. Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study. Clin Lymphoma Myeloma Leuk. 2022;22:e405\u201313.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"354_CR12","doi-asserted-by":"crossref","unstructured":"Abreu GA, Queiroz J, Nogueira da Silva TL, et al. Multiple lines of therapy and progression to next lines in multiple myeloma patients: real-world studies in Argentina (TOTEMM-A) and Brazil (TOTEMM-B). Blood. 2024;144:5161.","DOI":"10.1182\/blood-2024-193141"},{"key":"354_CR13","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood"},{"key":"354_CR14","unstructured":"European Medicines Agency. EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. 2023. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep. Accessed Mar 2025."},{"key":"354_CR15","unstructured":"U.S. Food & Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Accessed Feb 2025."},{"key":"354_CR16","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase\u00a03, open-label, randomised study. Lancet Haematol. 2023;10:e801\u201312.","journal-title":"Lancet Haematol"},{"key":"354_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393\u2013407.","journal-title":"N Engl J Med"},{"key":"354_CR18","unstructured":"Hungria V, Robak P, Hus M, et al. 772: Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma: overall survival analysis and updated efficacy outcomes of the phase 3 DREAMM-7 trial. American Society of Hematology (ASH) Annual Meeting; 7\u201310 December 2024; San Diego, CA, USA."},{"key":"354_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391:408\u201321.","journal-title":"N Engl J Med"},{"key":"354_CR20","doi-asserted-by":"crossref","unstructured":"Loubert A, Bunod L, M\u2019Hari M, Pompilus F, Purser M, McNamara S. 3358: the impact of patient-reported adverse events on quality of life: an analysis of the DREAMM-7 and DREAMM-8 randomized controlled trials. American Society of Hematology (ASH) Annual Meeting; San Diego, CA, USA.","DOI":"10.1182\/blood-2024-200299"},{"key":"354_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31:589\u2013604.","journal-title":"J Ocul Pharmacol Ther"},{"key":"354_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018;36:121\u201335.","journal-title":"Invest New Drugs"},{"key":"354_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9:889\u2013911.","journal-title":"Ophthalmol Ther"},{"key":"354_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","volume":"11","author":"S Lonial","year":"2021","unstructured":"Lonial S, Nooka AK, Thulasi P, et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021;11:103.","journal-title":"Blood Cancer J"},{"key":"354_CR25","doi-asserted-by":"crossref","unstructured":"Hungria V, Robak P, Hus M, et al. P-396: Characterization and management of ocular events in patients treated with belantamab mafodotin plus bortezomib and dexamethasone in the DREAMM-7 study. International Myeloma Society (IMS) Annual Meeting; 25\u201328 September 2024; Rio de Janeiro, Brazil.","DOI":"10.1016\/S2152-2650(24)02298-5"},{"key":"354_CR26","doi-asserted-by":"crossref","unstructured":"Quach H, Dimopoulos MA, Beksac M, et al. P-413: characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study. International Myeloma Society (IMS) Annual Meeting; 25\u201328 September 2024; Rio de Janeiro, Brazil.","DOI":"10.1016\/S2152-2650(24)02315-2"},{"key":"354_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease\u00a0Index. Arch Ophthalmol. 2000;118:615\u201321.","journal-title":"Arch Ophthalmol"},{"key":"354_CR28","unstructured":"Dimopoulos MA, Beksac M, Pour L, et al. LB3440: results from the randomized phase\u00a03 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed\/refractory multiple myeloma. 29th European Hematology Association Congress; 13\u201316 June 2024; Madrid, Spain."},{"key":"354_CR29","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"354_CR30","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364.","journal-title":"Blood"},{"key":"354_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2024-198669","volume":"144","author":"SZ Usmani","year":"2024","unstructured":"Usmani SZ, Mielnik M, Garg M, et al. Phase\u00a0I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: DREAMM-9 updated interim analysis. Blood. 2024;144:497.","journal-title":"Blood"},{"key":"354_CR32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.clml.2022.08.003","volume":"22","author":"T Atieh","year":"2022","unstructured":"Atieh T, Atrash S, Ahmed N, et al. Belantamab in combination with dexamethasone in patients with triple-class relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22:912\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"354_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/ICL.0000000000000544","volume":"45","author":"X Zhang","year":"2019","unstructured":"Zhang X, Vadoothker S, Munir WM, Saeedi O. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019;45:11\u20138.","journal-title":"Eye Contact Lens"},{"key":"354_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.27219","volume":"99","author":"M Gavriatopoulou","year":"2024","unstructured":"Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, et al. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase\u00a01\/2 study. Am J Hematol. 2024;99:502\u20134.","journal-title":"Am J Hematol"},{"key":"354_CR35","doi-asserted-by":"publisher","first-page":"1274659","DOI":"10.3389\/fonc.2023.1274659","volume":"13","author":"A Cardellino","year":"2023","unstructured":"Cardellino A, Correll JR, Martin M, Gorsh B, Sapra S, Popat R. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed\/refractory multiple myeloma in the DREAMM-2 study. Front Oncol. 2023;13:1274659.","journal-title":"Front Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00354-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00354-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00354-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:03:53Z","timestamp":1757207033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00354-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00354-2","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"V\u00e2nia Hungria received consulting fees and payment\/honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from BMS, GSK, J&J, Sanofi, and Takeda; and received support for attending meetings\/travel, and participated in a Data Safety Monitoring Board or Advisory Board for GSK and J&J. Virginia Abello Polo received consulting fees from Janssen, Novartis, and GSK; and support for attending meetings\/travel from Amgen and Roche. Edvan Q Crusoe received consultancy fees from GSK, grants from J&J; payment\/honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from J&J, Pfizer, Takeda, BMS, Amgen, and GSK; and participated in a Data Safety Monitoring Board or Advisory Board for J&J, Pfizer, Takeda, Amgen, and GSK. Patricio G Schlottmann received consulting fees from GSK, Roche\/Genentech, Novartis, AbbVie, Janssen, Ocular Therapeutics, Eyepoint, Merck\/Eyebio, Oculis, 4DMT, ViewMind, Merit, and Adverum. Jorge C Torres Flores received consultancy fees from GSK, payment for expert testimony and payment\/honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amgen; and support for attending meetings\/travel from Amgen, AbbVie, GSK, Roche, and BMS. Angelo Maiolino received consultancy fees from J&J, Pfizer, and GSK; payment\/honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from J&J, Pfizer, Takeda, BMS, Amgen, GSK, and Sanofi; and participated in a Data Safety Monitoring Board or Advisory Board for J&J, Pfizer, Takeda, BMS, GSK, and Sanofi. Ariel Corzo, Michel E Farah, Nat\u00e1lia A Iutaka, Gracia A Martinez, Aline G Ram\u00edrez Alvarado, Sim\u00f3n Romano-Bucay, and Cristian M Seehaus received consultancy fees from GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}